SEE CLEARLY. ACT DECISIVELY.
It's time to rethink response assessment.
Foresight CLARITYTM delivers early and accurate response assessment powered by our PhasED-SeqTM ultra-sensitive ctDNA MRD technology.
"Foresight was the partner we were waiting for due to [their] robust evidence and reputation as the most reliable and sensitive MRD assay in development for LBCL."
David Chang, M.D., Ph.D.
CEO, Allogene Therapeutics
30-40% of DLBCL patients are likely to relapse 1-2 years after first-line therapy.1
Foresight CLARITY predicts relapse risk immediately at the end of treatment. That's up to 200 days sooner than relying on PET/CT for relapse diagnosis.2
Lower limit of detection. Higher standards.
1 part
per million
95%
>90%
>97%
Analytical sensitivity (or limit of detection)2
Confidence level in assay performance3
Clinical sensitivity at EOT2
Clinical specificity at EOT2
From research to diagnostic development
3x faster
Accelerate clinical trials up to 12 months with earlier endpoint measurement
Across multiple studies, MRD detection by Foresight CLARITY accurately stratified patient response at end of treatment. 3,4
Event-free survival (EFS) with MRD may accelerate clinical trial readouts by up to a year than progression-free survival (PFS) alone.3
Time to accrue 25% event rate
Read our latest data on the prognostic utility of Foresight CLARITY in DLBCL and FL
At Foresight, we are raising the bar on what it means to be ‘ultra-sensitive.’ It is not enough to be sensitive. MRD tests must be highly accurate and reliable, with clinical relevance.
LOD95 - the standard in assay sensitivity.
The lowest limit detection expected across all clinical samples with a 95% confidence.
Foresight CLARITY Assay Performance in DLBCL*
Earlier relapse detection in DLBCL
Interested in additional cancer indications?
Recent Scientific Presentations
10-6 was shown to be the optimal limit of detection for consistent and accurate response assessment across multiple time points before, during, and after therapy.3
Foresight CLARITY predicted deep, durable remission to liso-cel as early as fifteen days into treatment.5
© 2024 Foresight Diagnostics, Inc. The tests described have been developed and their performance characteristics have been determined by the CLIA-registered laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). All Rights Reserved.
Citations
1. Nuvvula S, Dahiya S, Patel SA. The novel therapeutic landscape for relapsed/refractory diffuse large B cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22(6):362–372. doi: 10.1016/j.clml.2021.11.010
2. Kurtz, et al., Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma, American Society of Hematology Annual Meeting (2023)
3. Goldstein, et al., Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy, American Society of Hematology Annual Meeting (2023)
4. Roschewski et al., End of Treatment Response Assessment After Frontline Therapy for Aggressive B-cell Lymphoma: Landmark Comparison of a Singular PET/CT scan vs Ultrasensitive Circulating Tumor DNA, American Society of Hematology Annual Meeting (2023); Sworder, et al., Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World ctDNA Study, American Society of Hematology Annual Meeting (2023)
5. Stepan, et al., Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study, American Society of Hematology Annual Meeting (2023)
Want to stay up to date? Join our mailing list for updates on our research and products.
Foresight CLARITY for Lymphoma
Diffuse Large B-cell Lymphoma (DLBCL)
Follicular Lymphoma
Hodgkin's Lymphoma
*These performance characteristics have not been reviewed by the FDA
Foresight CLARITY is a liquid-biopsy powered platform that detects minimal residual disease (MRD) from circulating tumor DNA (ctDNA), an early indicator of cancer relapse.
Foresight CLARITY for Solid Tumor
Non-small Cell Lung Cancer (NSCLC)
Breast Cancer
Our Clinical Research Assays